Hyperthermic Intraoperative Thoracoabdominal Chemotherapy by Sugarbaker, Paul H. et al.
Hindawi Publishing Corporation
Gastroenterology Research and Practice
Volume 2012, Article ID 623417, 7 pages
doi:10.1155/2012/623417
Research Article
Hyperthermic Intraoperative Thoracoabdominal Chemotherapy
Paul H.Sugarbaker,1 DavidChang,2 and O. Anthony Stuart1
1Washington Hospital Center, Washington Cancer Institute, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA
2Westat, 1600 Research Boulevard, Rockville, MD 20850-3129, USA
Correspondence should be addressed to Paul H. Sugarbaker, paul.sugarbaker@medstar.net
Received 6 February 2012; Accepted 1 March 2012
Academic Editor: Pompiliu Piso
Copyright © 2012 Paul H. Sugarbaker et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for selected
patients with pseudomyxoma peritonei (PMP) and diﬀuse malignant peritoneal mesothelioma (DMPM). Tumor inﬁltration
of the hemidiaphragm requiring partial resection occurs as a result of large volume and/or invasive disease at this anatomic
site. Transmission of disease from abdomen to chest is a great danger in this group of patients. From a prospective database,
patients who had diaphragm resection and then hyperthermic thoracoabdominal chemotherapy (HITAC) as a component of
a cytoreductive surgical procedure were identiﬁed. Data from control patients receiving HIPEC or hyperthermic intrathoracic
chemotherapy(HITOC)wereanalyzedforcomparison.Themorbidity,mortality,survival,andrecurrenceratewithinthethoracic
space were presented. Thirty patients had partial resection of a hemidiaphragm as part of a cytoreductive surgical procedure that
utilizedHITAC.Thepharmacologicbeneﬁtofintracavitarychemotherapyadministrationwasdocumentedwithanareaunderthe
curve ratio of intracavitary concentration times time to plasma concentration times time of 27 ± 10 for mitomycin C and 75 ± 26
for doxorubicin. Comparing percent chemotherapy absorbed for a ninety-minute treatment showed the largest for HIPEC, then
for HITAC, and lowest for HITOC. The incidence of grade 3 and 4 adverse events was 43%. There was no mortality. Adjustments
in the chemotherapy dose are not necessary with HITAC. The morbidity was high, the survival was acceptable, and intrathoracic
recurrence was low.
1.Introduction
Increasing interest in the surgical management of peritone-
al metastases from gastrointestinal cancer is evident from
the many recent publications on this subject [1–5]. Improve-
ments in surgical technology by using cytoreductive surgery
with peritonectomy are a necessary part of these new man-
agementstrategies [6]. Also, perioperative chemotherapy, es-
pecially hyperthermic intraperitoneal chemotherapy, has
routinelybeenaddedtothesurgicalintervention[7].Gastro-
intestinal cancer with peritoneal metastases may accumulate
in large volume on the undersurfaces of the hemidiaphra-
gms.Invasionofthehemidiaphragm,especiallyitstendinous
midportion, may be required in order to achieve optimal cy-
toreduction. The perioperative chemotherapy and clinical
management strategy for patients whose cytoreduction re-
quired partial excision of a hemidiaphragm are the subject of
this paper.
2.MaterialsandMethods
Permission to accumulate and analyze these data was ob-
tained from the ethics committee of our institution. From a
prospective database of patients with appendiceal mucinous
neoplasms with peritoneal metastases, colon cancer patients
with peritoneal metastases, gastric cancer with peritoneal
metastases, and peritoneal mesothelioma patients; we iden-
tiﬁed those in whom a diaphragm resection was required
at the time of cytoreductive surgery. The clinical features of
these patients including their diagnosis, age, gender, and dia-
phragm resected (right versus left versus both right and left)
were tabulated.
All of these patients had an attempt at complete removal
of their peritoneal surface malignancy prior to the initiation
of the hyperthermic intraoperative chemotherapy [8]. In
all of these patients disease inﬁltration of the diaphragm
required resection of a portion of the diaphragm in order to2 Gastroenterology Research and Practice
try and achieve the goal of complete cytoreduction. If even a
small transection of the hemidiaphragm occurred, the entire
central tendinous portion of the diaphragm was resected.
The pleural space was visualized as possible through the
opening in the hemidiaphragm. If cancer nodules within the
thoracic space were visualized, one or several were biopsied.
An attempt at pleurectomy was not added to the treatment
strategy. This was to allow the free ﬂow of hyperthermic
intraoperative chemotherapy into the thoracic cavity from
the abdominal cavity. To deliver the chemotherapy there
was a single inﬂow catheter that was periodically moved
aroundtheabdominalspace.Therewerethreeclosedsuction
drains within the abdomen and a thoracostomy tube within
the chest. The chest tube was 28 French diameter and
many times larger than the intraabdominal drainage tu-
bes thereby favoring heated chemotherapy ﬂow from ab-
domen, through the diaphragm, and into the thoracic
cavity.
During the chemotherapy treatment specimens from
blood and the thoracoabdominal ﬂuid were obtained at 15-
minute intervals for 60 minutes and then a single sample at
90minutes.Thesesampleswerecentrifugedtoremovedebris
or red blood cells. The cell-free solutions were frozen and
storedforhigh-performanceliquidchromatography(HPLC)
analysis which was performed within 1 week.
The dose of chemotherapy was 15mg/m2 for mitomycin
Ca n d1 5m g / m 2 for doxorubicin. The volume of chemother-
apy solution was always 1.5 liters/m2 of body surface. This
was a volume of chemotherapy solution that would ﬁll the
peritoneal space and the thoracic space at the initiation of
the combined thoracoabdominal chemotherapy lavage.
Following the hyperthermic thoracoabdominal chemo-
therapy treatments, all chemotherapy ﬂuid was removed
from the abdomen and pelvis. The volume of chemotherapy
solution was carefully measured so that the total milligrams
of chemotherapy that left the thoracoabdominal space into
the body compartment could be calculated.
Following the chemotherapy treatments, the diaphragm
wasclosedinaroutinefashionwithinterruptedandcontinu-
oussutures.Thereafter,reconstructionofthegastrointestinal
tract and closure of the abdomen occurred.
Pharmacokinetic studies of mitomycin C and doxoru-
bicin were performed on peritoneal ﬂuid and plasma in
order to determine the relative exposure (area under the
curve ratio) of chemotherapy in the peritoneal and pleural
ﬂuid versus chemotherapy in the plasma. The drug concen-
trations in these ﬂuids were determined by HPLC assay as
previously described [9, 10]. Also, 25 patients in whom the
regional chemotherapy was conﬁned to the peritoneal cavity
(HIPEC) matched for age, diagnosis, and extent of disease
(except for diaphragm resection) who had mitomycin C and
doxorubicin pharmacokinetics determined were used as a
comparison for data from patients who had both thoracic
and abdominal chemotherapy lavage (HITAC). In a third
groupofpatients,thehyperthermicchemotherapytreatment
was limited to the thoracic cavity after pleurectomy and
decortication (HITOC). The percent of the chemothera-
py absorbed in these three groups of patients was com-
pared.
Table 1: Clinical and demographic information on patients hav-
ing hyperthermic intraoperative thoracoabdominal chemotherapy
(HITAC), patients having hyperthermic perioperative chemother-
apy (HIPEC), and patients having hyperthermic intrathoracic
chemotherapy (HITOC).
DEMOGRAPHICS HITAC HIPEC HITOC
Total patients 30 25 5
Male 14 10 1
Female 16 15 4
Diagnosis
Appendix 16 23 4
Colon 5 2
Peritoneal mesothelioma 8 1
Gastric 1
Right 23 Not applicable 3
Left 6 Not applicable 2
Right and left 1 Not applicable 0
Complete cytoreduction
CC-0/CC-1 18 21 5
Incomplete cytoreduction
CC-2/CC-3 12 4 0
Median age 50 48 50
Range 33–68 33–67 43–58
2.1. Statistics. AS t u d e n t ’ st-test (Microsoft Excel 2007) was
used to compare the percent of total intracavitary chemo-
therapy absorbed over 90 minutes from the thoracoabdom-
inal space versus the thoracic space. Survival analyses were
prepared using the Kaplan-Meier method.
A postoperative prospective morbidity/mortality data-
base was maintained on these patients. There were 8 cate-
gories of events and 47 items scored in the eight categories as
previouslydescribed[11].Also,followuponthesepatientsin
terms of long-term survival and recurrence of disease within
the hemithorax was determined.
3. Results
There were a total of 30 patients with peritoneal metastases
betweenJanuary2000andSeptember2011whosecytoreduc-
tive surgery required a diaphragm excision. Sixteen patients
had appendiceal mucinous neoplasm, 5 colon cancer, 8
peritoneal mesothelioma, and 1 gastric cancer. The median
a g eo ft h e s ep a t i e n t sw a s5 0w i t har a n g eo f3 3t o6 8y e a r s .
There were 16 female patients and 14 male patients. The
right pleural space was entered in 23 patients, the left pleural
space was entered in 6 patients, and both right and left
hemidiaphragms partiallyresectioninasingle patient. Atthe
close of the cytoreductive surgery, a CC-0/CC-1 (complete)
cytoreduction was recorded in 18 patients and a CC-2/CC-3
(incomplete) cytoreduction in 12 (Table 1). In 6 patients the
cytoreduction was scored as incomplete because of residual
disease within the thorax.
In the 25 control patients with hyperthermic chemother-
apy limited to the peritoneal space, 23 had a diagnosis of
appendiceal mucinous neoplasm, and two a diagnosis ofGastroenterology Research and Practice 3
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Figure 1: Pharmacokinetics of mitomycin C in 12 patients with
simultaneousintraabdominalandintrathoracicchemotherapyused
in conjunction with cytoreductive surgery.
coloncancer.Inthethreepatientswhoreceivedintrathoracic
mitomycin C, all had an appendiceal mucinous neoplasm.
In the four patients who received intrathoracic doxorubicin,
three had appendiceal mucinous neoplasm and one had
peritoneal mesothelioma (Table 1).
3.1. Pharmacokinetics of Hyperthermic Chemotherapy in
Thoracic and Abdominal Cavity (HITAC). In 12 patients
complete pharmacokinetic data was available so that the
mitomycin C concentrations in ﬂuid from the thoracic and
abdominal space could be determined along with plasma
concentrations of this drug. Figure 1 shows the area under
the curve for thoracoabdominal mitomycin C as compared
to the area under curve for plasma mitomycin C. The area
under the curve ratio was 27 ± 10. Nine of these patients
had appendiceal neoplasms, 2 colon cancer, and 1 peritoneal
mesothelioma.
Similar data was obtained from the same 12 patients who
received intrathoracic and abdominal doxorubicin. The area
under the curve for thoracoabdominal ﬂuid as compared to
the area under the curve forplasma is shown in Figure 2.Th e
area under the curve ratio was 75 ± 26.
3.2. Comparison of Thoracic and Abdominal Chemotherapy
Treatment (HITAC) to a Chemotherapy Lavage Limited to the
Abdominal Space (HIPEC) and to a Chemotherapy Lavage
Limited to the Thoracic Space (HITOC). In 25 control
patients in whom hyperthermic intraoperative chemother-
apy treatment was limited to the abdominal and pelvic space
(HIPEC), the percent of drug absorbed from the peritoneal
cavityoverthe90minutesoftreatmentwasdetermined.Also
in three patients the hyperthermic mitomycin C treatments
were limited to the thoracic cavity (HITOC). These results
were compared to the percent of chemotherapy absorbed in
patients with thoracic and abdominal chemotherapy lavage
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Figure 2: Pharmacokinetics of doxorubicin in 12 patients with
simultaneous intraabdominal and intrathoracic chemotherapy
administration in conjunction with cytoreductive surgery.
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Figure 3: Comparison of percent mitomycin C absorbed after 90
minutesoftreatmentfromtheabdominalcavity,combinedthoracic
and abdominal cavity, and the thoracic cavity alone.
(HITAC). Figure 3 shows the results with mitomycin C. In
patients with HIPEC mitomycin C treatment, 75% of the
total drug administered at time zero was absorbed at 90
minutes. In patients with HITAC 67% was absorbed. In the
patients with HITOC, only 41% was absorbed from this
space at 90 minutes. This was highly signiﬁcant as compared
to the HITAC (P = .0015). Figure 4 shows similar data
for doxorubicin. Very similar percent absorption over 90
minutes occurred in patients receiving HIPEC as compared
toHITAC.ForHITOCwithdoxorubicin,72%wasabsorbed.4 Gastroenterology Research and Practice
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Figure 4: Comparison of percent of doxorubicin absorbed after
90 minutes of treatment from the abdominal cavity, thoracic and
abdominal cavity, and the thoracic cavity alone.
This was statistically diﬀerent when compared to the HITAC
(P<. 001).
3.3. Prospective Morbidity and Mortality Data. The prospec-
tive morbidity/mortality database on this group of 30
patients showed that no deaths occurred. In 11 of these
30 patients (37%) at least one grade III adverse event was
recorded. Also in 8, at least one grade IV adverse event
occurred (27%). The combined incidence of grade III and
IV events was 43%. There was a single adverse grade III or
IV event in 3 patients. However, most patients who had one
adverse event experienced others. Five had two adverse grade
III or IV events, one had three adverse events, one had 4
adverse events, and one had 7 adverse events recorded. The
30 adverse events recorded in 13 patients are listed inTable 2.
3.4. Survival Data. The overall survival of these groups
of patients is presented in Figure 5. Median survival for
appendiceal malignancy patients was 129 months, for
peritoneal mesothelioma patients 44.6 months, and for
colon cancer patients 13.4 months. In the analysis of the
appendiceal mucinous neoplasm patients, adenomucinosis
histology (one patient) was combined with those patients
with peritoneal mucinous carcinoma (15 patients). The
single gastric cancer patient died at 5 months.
3.5.Recurrence. Allpatientshavebeenfollowedtodetermine
if cancer progressed within the thoracic cavity after HITAP.
A single patient with appendiceal malignancy who had
both the right and left thoracic space entered at the time
of cytoreduction recurred within the pleural space. Two
mesothelioma patients recurred within the pleural space.
4. Discussion
4.1. Pleural Disease Progression in Patients with and without
Hyperthermic Intraoperative Thoracoabdominal Chemother-
apy (HITAC). In a previous publication looking at patterns
of failure in the treatment of patients with pseudomyxoma
peritonei, our group reported 6 of 8 patients to develop
disease within the ipsilateral thorax if the pleural space was
entered as a result of a subdiaphragmatic peritonectomy
[12]. In these patients the diaphragm was closed prior to
theintraperitonealchemotherapytreatment.Therefore,little
if any direct contact of chemotherapy solution with the
pleural space could occur. In these eight patients, 75% had
iatrogenic dissemination of disease from abdominal space to
thoracic cavity as a result of an interruption of the integrity
of the hemidiaphragm. In the 118 patients in Zoetmulder’s
manuscript, pleural dissemination did not occur unless
the pleural space was entered. These patients all received
early postoperative intraperitoneal chemotherapy (EPIC). In
contrast, we have followed-up all 16 appendiceal malignancy
patients treated with HITAC for disease progression within
the pleural space. Pleural progression occurred in a single
patient. This wasthe patient whorequired both right and left
diaphragm resection as the time of her primary cytoreduc-
tion. These data strongly suggest that HITAC is an essential
part of the treatment of peritoneal metastases if diaphragm
resection is required.
4.2. Abdominal versus Thoracic and Abdominal versus Tho-
racic Chemotherapy Lavage. The pharmacokinetic advantage
of chemotherapy administration into the peritoneal cavity
has been described in many prior publications. Van der
Speeten and colleagues presented doxorubicin levels in
plasma, peritoneal ﬂuid, and tumor nodules. The ratio of
drug concentration within the peritoneal space as compared
to that present in the plasma was 73 times greater within
the peritoneal ﬂuid. Doxorubicin levels within tumor tissue
were 1.8 times higher than in the peritoneal ﬂuid [13].
Likewise, pharmacokinetic data regarding intraperitoneal
administrationofmitomycinChasbeenreportedinthepast.
Van der Speeten and colleagues showed that the exposure
of peritoneal surfaces to be 26 times higher than exposure
within the plasma [9]. Technical diﬃculties with extracting
mitomycin C from body tissues precluded the data regarding
tissue levels of mitomycin C [9]. Because of the large increase
in total diﬀusion surface when the pleural space is added to
the abdominal space for HITAC, we expected a more rapid
clearance of the intracavitary chemotherapy [14].
To our surprise adding the pleural space to the HIPEC
procedure did little to change the pharmacokinetics of the
chemotherapy. This is important in that the percent of
chemotherapy absorbed from the thoracic and abdominal
space should predict the likelihood of hematologic toxicity
in this group of patients. Apparently, the absorption of
chemotherapy from the pleural space through the parietal
pleura and visceral pleura is considerably less eﬃcient
than from the abdominal and pelvic cavity. Data showed
the clearance of mitomycin C over 90 minutes to be
approximately 75% from the abdominal space, 67% fromGastroenterology Research and Practice 5
Table 2 :C a u s e so fg r a d eI I Io rI Va d v e r s ee v e n t s .T h e r ew e r e3 0a d v e r s ee v e n t si n1 3p a t i e n t s( 4 3 % ) .
III IV III + IV (%)
Line sepsis 4 0 4 (13)
Anemia (Hgb < 6.5) 3 0 3 (10)
Pneumonia 0 2 2 (7)
Venous thrombosis 2 0 2 (7)
Anastomotic leak 0 1 1 (3)
Intraabdominal abscess 0 1 1 (3)
Urinary tract infection 3 0 3 (10)
Profound neutropenia (WBC < 1000) 2 1 3 (10)
Hartmann stump leak 0 1 1 (3)
Unscheduled hospital readmission 1 1 2 (7)
Pleural eﬀusion requiring thoracentesis 2 0 2 (7)
Postoperative bleed requiring reoperation 0 3 3 (10)
Renal failure requiring hemodialysis 0 1 1 (3)
Respiratory failure requiring tracheostomy 0 1 1 (3)
Bile leak from liver surface requiring reoperation 0 1 1 (3)
Total 17 13 30 (43)
the thoracoabdominal space, and only 41% when the lavage
is limited to the pleural space. Also, for doxorubicin, 90%
of the drug was absorbed from the abdominal space, 90%
from the thoracoabdominal space, and only 72% absorbed
from the pleural space. This lack of permeability of the
pleura to cancer chemotherapy accounts for the similarities
of drug absorption from abdominal space as compared to
thoracoabdominal space despite a large increase in the total
diﬀusion surface.
This observation is important in this group of patients.
It indicates to us that the dose of chemotherapy that
would be used to treat the abdomen and pelvis can be
estimated to be the same dose as that to treat the thorax and
abdominalspace.NoadjustmentsinthestandardizedHIPEC
chemotherapy orders are necessary in this clinical situa-
tion.
4.3. Adverse Events with Diaphragm Resection. In this group
of patients the resection of the hemidiaphragm was asso-
ciated with a 43% incidence of grade III or IV adverse
events. There was no mortality. Our most recent morbidity
data showed a 0.7% mortality, a grade III incidence of 20%
and grade IV of 12% with cytoreductive surgery limited to
the abdomen and pelvis [15]. Our data in 30 patients with
diaphragm resection, chemotherapy lavage of both thorax
and abdomen, and then a suture repair of the diaphragm
showed no mortality, a grade III incidence of 37%, and
a grade IV of 27%. Apparently, the subdiaphragmatic
peritonectomy with partial excision of a hemidiaphragm
identiﬁes a group of patients with extensive cytoreduction
and a greater likelihood of morbidity. However, we think
these data show that cytoreductive surgeons should not
hesitate to perform a resection of the tendinous midportion
of the hemidiaphragm in order to achieve a CC-0/CC-1
cytoreduction and combine this surgery with HITAP. Bene-
ﬁtsareexpectedintermsoflocalcontrolusingthisapproach.
4.4. Survival of Patients Having Diaphragm Resection.
Figure 5 shows the survival with diaphragm resection as a
part of a cytoreductive surgical procedure. The appendiceal
malignancy patients showed the longest median survival
(129 months). Also, a median survival of 45 months for
peritoneal mesothelioma patients is acceptable. One of the
ﬁve colon cancer patients who required diaphragm resection
for a complete cytoreduction was a long-term survivor.
4.5.CurrentRecommendationsforManagementofDiaphragm
Resection. Our current recommendation for management of
diaphragm whose central tendon is inﬁltrated by tumor is
as follows. If during the right or left subdiaphragmatic peri-
tonectomy it becomes clear that partial resection of the dia-
phragm is necessary, the dissection beneath the diaphragm
ceases and the cytoreduction moves to a diﬀerent part of the
abdomenandpelvis.Thecytoreductioniscompletedasthor-
oughly as possible at all other sites within the abdomen and
pelvis with the exclusion of the hemidiaphragm. Then, there
is a vigorous six liter irrigation of the entire abdomen and
pelvisinordertomechanicallyclearfreecancercellsfromthe
abdomen and pelvis. Alternatively, the cytoreduction may
turn out to be incomplete so that diaphragm resection is not
required to ﬁnish the CC-2/CC-3 cytoreduction.
After this mechanical cleansing of the abdomen and
pelvis of cancer cells, the required resection of the hemidi-
aphragm occurs. The specimen is carefully labeled in terms
of its abdominal and thoracic orientation. It is important
to determine if the disease has invaded full thickness
through the hemidiaphragm. The thoracic cavity is carefully
inspected for nodules of mucinous cancer or mesothelioma.
Nodules that can be excised without extensive pleurectomy
are removed and also submitted for permanent histopatho-
logic study. Abdominal drains and an inﬂow catheter are
placed.Athoracostomytubeisplacedwithinthechestcavity.
The three abdominal drains and the thoracostomy tube are6 Gastroenterology Research and Practice
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Figure 5: Survival for 29 patients who had a resection of the diaphragm as part of the cytoreductive surgical procedure combined
with hyperthermic intraoperative thoracoabdominal chemotherapy (HITAC). (a) appendiceal malignancy (N = 16), (b) peritoneal
mesothelioma (N = 8), and (c) colon cancer (N = 5).
simultaneously used for drainage of the chemotherapy. The
inﬂow catheter is sequentially placed in the pelvis, the right
paracolic sulcus, the left paracolic sulcus, under the intact
hemidiaphragm, and ﬁnally through the diaphragm into the
chest. After the chemotherapy lavage is complete the ﬂuid
is suctioned from the abdomen and pelvis. A count of all
laparotomy pads is obtained and then the chest cavity is
closed. A series of interrupted and running #1 Vicryl sutures
(Ethicon, Cincinnati, OH) are used. The use of a prosthetic
diaphragm patch is seldom, if ever, necessary.
4.6. Open versus Closed Hyperthermic Intraperitoneal Chemo-
therapy. Currently, there remains some controversy regard-
ing the methodology for administration of hyperthermic
intraperitoneal chemotherapy. In the closed technique there
is less danger, theoretically, for aerosol contamination of
the operating theater. With the closed technique, if the
diaphragm was opened as a result of cancer inﬁltration, this
opening would be closed prior to the initiation of HIPEC.
This is a theoretical disadvantage in that tumor cells can
only be mechanically removed from the thoracic cavity ra-
therthantreatedwiththechemotherapy.Intheopenmetho-
dology the combined abdomen and chest cavities are sim-
ultaneously lavaged with the chemotherapy solution for the
full 90 minutes. Data from this paper suggests that the
administration of HITAC does not require dose adjustments
of the chemotherapy as compared to HIPEC. Also, these
data suggest that local control as a result of HITAC within
the thoracic space is excellent. Following the hyperthermic
chemotherapy lavage of the contaminated pleural surfaces,
the diaphragm would be closed leaving a large bore thora-
costomy tube within the thoracic cavity. A separate inﬂow
catheter into the chest was not necessary because of theGastroenterology Research and Practice 7
large volume of chemotherapy outﬂow through the open
diaphragm and out through the thoracostomy tube. A theo-
retical and probably actual clinical advantage of the open
method over the closed method occurs in patients required
to have diaphragm resection.
4.7. Rationale for HITAC in Patients with CC-2/CC-3 Cytore-
duction. The data regarding palliative beneﬁt of HIPEC
in patients with CC-2/CC-3 cytoreduction has never been
rigorously studied. There is no doubt that incomplete
cytoreduction is associated with a poor prognosis in appen-
dicealcancer,colorectalcancer,andperitonealmesothelioma
patients. However, when added to an extensive debulking
procedure, the hyperthermic intracavitary chemotherapy
may achieve a partial response and prolong the patient’s
life. This may be most likely if all adhesions on bowel loops
are separated so the HIPEC is in contact with all peritoneal
surfaces. Also, any patients who have ascites as a component
of their peritoneal surface malignancy should receive intra-
cavitary chemotherapy in order to guard against debilitating
ascites occurring as the disease progresses. Garofalo and
Valle showed that HIPEC is an excellent treatment for the
management of cancerous ascites [16].
5. Conclusions
HITAC is a treatment option for cytoreductive surgery in
appendiceal and DMPM patients when the diaphragm must
b ep a rt i a l l yr e s e c t e da sp a rto fac yt o r e d u c t i v es u r gi c a lp r o c e -
dure. The pharmacokinetic advantage of direct intracavitary
administration is preserved when HITAC is utilized. Also,
judgments in the chemotherapy dose were not found to be
necessary with HITAC as compared to HIPEC. An assess-
ment of adverse events showed a 43% incidence of grade III
or grade IV adverse events which is higher than reported for
most groups of patients undergoing cytoreductive surgery
and HIPEC. However, the survival was acceptable and the
incidence of intrathoracic recurrence was low.
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